• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum

    Simply Wall St·08/13/2026 08:37:17
    Listen to the news
    • ADMA Biologics recently reported its second-quarter 2026 results, with sales of US$124.4 million and net income of US$37.82 million, and it reaffirmed full-year revenue guidance of US$530 million to US$560 million.
    • The combination of higher quarterly and year-to-date earnings per share versus last year and maintained revenue expectations highlights management’s confidence in the company’s current operating trajectory.
    • Next, we’ll consider how ADMA’s reaffirmed 2026 revenue guidance could influence the existing investment narrative around margin resilience and growth.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    ADMA Biologics Investment Narrative Recap

    To own ADMA Biologics, you need to believe its focused immunoglobulin franchise and yield enhancement process can support resilient margins and growing cash generation, despite product and plasma supply concentration. The latest quarter’s solid profitability and reaffirmed US$530 million to US$560 million revenue guidance do not materially change the near term catalyst, which remains execution on margin resilience, or the key risk around dependence on a narrow product set and a complex plasma supply chain.

    The most relevant recent announcement here is ADMA’s confirmation of 2026 revenue guidance at US$530 million to US$560 million, following prior guidance that had pointed to revenue above US$635 million. In the context of earlier bullish expectations, this reset reinforces how sensitive the thesis is to production scaling, yield efficiency, and plasma availability, and why any bumps in those areas can quickly shift how investors think about both upside potential and risk.

    Yet behind the reaffirmed guidance, investors should be aware of how ADMA’s reliance on plasma collection and complex manufacturing could...

    Read the full narrative on ADMA Biologics (it's free!)

    ADMA Biologics' narrative projects $814.2 million revenue and $330.4 million earnings by 2029. This requires 16.9% yearly revenue growth and roughly a $165 million earnings increase from $165.4 million today.

    Uncover how ADMA Biologics' forecasts yield a $17.60 fair value, a 80% upside to its current price.

    Exploring Other Perspectives

    ADMA 1-Year Stock Price Chart
    ADMA 1-Year Stock Price Chart

    Before this update, the most optimistic analysts were penciling in revenue near US$1.0 billion and almost US$400 million in earnings by 2029, far more aggressive than consensus, so you should recognize how widely views can differ and consider how this quarter’s guidance reset might shift those expectations.

    Explore 9 other fair value estimates on ADMA Biologics - why the stock might be worth over 3x more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your ADMA Biologics research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free ADMA Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ADMA Biologics' overall financial health at a glance.

    Searching For A Fresh Perspective?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.